NCT05001984View on ClinicalTrials.gov

Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

April 15, 2025

Study Completion Date

April 15, 2025

Conditions
Intracranial AtherosclerosisAcute Ischemic StrokeICAS - Intracranial Atherosclerosis
Interventions
DRUG

Alirocumab

Alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks.

Trial Locations (1)

613

Yenchu Huang, Chiayi City

All Listed Sponsors
collaborator

Chang Gung University

OTHER

lead

Chang Gung Memorial Hospital

OTHER